AdjuTec Pharma AS
AdjuTec Pharma is dedicated to developing and providing novel antibiotic resistance breakers to the global market. Their innovative technology offers a unique mechanism of action that inactivates bacterial defense enzymes and restores bacterial sensitivity to antibiotics. Their lead product, APC148, is a selective zinc chelator targeting bacterial metallo-ß-lactamase (MBL) enzymes, developed by Professor Pål Rongved and his group at the University of Oslo. The company is located in Oslo, Norway, and actively works on advancing solutions against antimicrobial resistance (AMR) through research, clinical trials, and strategic collaborations.
Industries
Nr. of Employees
small (1-50)
AdjuTec Pharma AS
St. Olavs gate 5, 0165 Oslo, Norway
Patents
Substituted phenazines and methods of treating cancer and bacterial diseases
US-11958842-B2
View DetailsSubstituted phenazines and methods of treating cancer and bacterial diseases
US-11046678-B2
View Details
Substituted phenazines and methods of treating cancer and bacterial diseases
US-11958842-B2
View DetailsSubstituted phenazines and methods of treating cancer and bacterial diseases
US-11046678-B2
View DetailsProducts
Metallo-β-lactamase inhibitor (lead compound)
A small-molecule selective zinc chelator that inhibits bacterial metallo-β-lactamase enzymes to restore sensitivity of resistant Gram-negative bacteria to existing antibiotics; developed for use in combination therapy and progressed through preclinical development into phase 1 clinical testing.
Metallo-β-lactamase inhibitor (lead compound)
A small-molecule selective zinc chelator that inhibits bacterial metallo-β-lactamase enzymes to restore sensitivity of resistant Gram-negative bacteria to existing antibiotics; developed for use in combination therapy and progressed through preclinical development into phase 1 clinical testing.
Services
Collaborative projects with academic and industry partners to evaluate enzyme inhibitors in microbiology assays, optimize synthesis and advance preclinical safety work.
Collaborative projects with academic and industry partners to evaluate enzyme inhibitors in microbiology assays, optimize synthesis and advance preclinical safety work.
Expertise Areas
- Antibiotic resistance therapeutics (enzyme inhibition strategies)
- Clinical trial management for early-phase studies
- Preclinical toxicology and safety assessment
- Chemical synthesis and CMC scale-up for small molecules
Key Technologies
- Metallo-β-lactamase inhibition via selective zinc chelation
- Small-molecule enzyme inhibitor chemistry
- In vitro microbiology testing of multi-drug-resistant Gram-negative bacteria
- Preclinical toxicology study methods
News & Updates
Starting microbiology and chemistry projects supported by external grants, including collaborations with the University of Oslo, RISE Sweden, and Kappa Solutions Oslo.
Indian authorities granted patent application for APC148, covering a large territory with high incidence of MBL-producing bacteria.
Met with Swedish authorities to support clinical Phase 1a study of APC148, planning to start in late 2023.
Received Qualified Infectious Disease Product (QIDP) designation for APC148 and meropenem, facilitating accelerated development.
Presented at the 6th AMR Conference in Basel, highlighting strategies to combat antimicrobial resistance.
A BBC documentary highlighting efforts to combat antimicrobial resistance.
Starting microbiology and chemistry projects supported by external grants, including collaborations with the University of Oslo, RISE Sweden, and Kappa Solutions Oslo.
Indian authorities granted patent application for APC148, covering a large territory with high incidence of MBL-producing bacteria.
Met with Swedish authorities to support clinical Phase 1a study of APC148, planning to start in late 2023.
Received Qualified Infectious Disease Product (QIDP) designation for APC148 and meropenem, facilitating accelerated development.
Presented at the 6th AMR Conference in Basel, highlighting strategies to combat antimicrobial resistance.
A BBC documentary highlighting efforts to combat antimicrobial resistance.